Is American Express a Buy, Sell or Hold?
American Express (NYSE:AXP) holds a notable place in Warren Buffett’s…
Buy
59
MNOV Quote, Financials, Valuation and Earnings
Last price:
$1.42
Seasonality move
:
-0.25%
Day range:
$1.39 - $1.45
52-week range:
$1.12 - $2.55
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.35x
Volume:
6.5K
Avg. volume:
14.9K
1-year change:
1.4%
Market cap:
$71.1M
Revenue:
$1M
EPS (TTM):
-$0.23
Analysts' Opinion
-
Consensus RatingMediciNova has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $8.33, MediciNova has an estimated upside of 474.71% from its current price of $1.45.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing 100% downside risk from its current price of $1.45.
Fair Value
-
According to the consensus of 2 analysts, MediciNova has 474.71% upside to fair value with a price target of $8.33 per share.
MNOV vs. S&P 500
-
Over the past 5 trading days, MediciNova has overperformed the S&P 500 by 15.92% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
MediciNova does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
MediciNova has grown year-over-year revenues for 1 quarter straight. In the most recent quarter MediciNova reported revenues of --.
Earnings Growth
-
MediciNova has grown year-over-year earnings for 0 quarters straight. In the most recent quarter MediciNova reported earnings per share of -$0.06.
Enterprise value:
30.8M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-2.89x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$14.6M | -$9.9M | -$12.7M | -$2.5M | -$3.2M | |
| EBITDA | -$14.6M | -$9.9M | -$12.7M | -$2.5M | -$3.2M | |
| Diluted EPS | -$0.28 | -$0.17 | -$0.23 | -$0.04 | -$0.06 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $60.7M | $72M | $59M | $51.2M | $41.1M | |
| Total Assets | $75.4M | $87.4M | $74.2M | $66.3M | $55.9M | |
| Current Liabilities | $2.2M | $2.8M | $3.2M | $3.3M | $3M | |
| Total Liabilities | $4.1M | $3.7M | $3.9M | $3.9M | $3.4M | |
| Total Equity | $71.3M | $83.7M | $70.2M | $62.4M | $52.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$12.9M | -$7.4M | -$10.6M | -$499.1K | -$1.9M | |
| Cash From Investing | -$40M | $39.9M | -$700 | $20 | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -$12.9M | -$7.5M | -$10.6M | -$499K | -$1.9M | |
MNOV
Sector
Market Cap
$71.1M
$35M
Price % of 52-Week High
56.86%
42.2%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.81%
1-Year Price Total Return
1.4%
-41.61%
Beta (5-Year)
0.750
0.742
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.36
200-day SMA
Sell
Level
$1.71
Bollinger Bands (100)
Sell
Level
1.52 - 2.12
Chaikin Money Flow
Sell
Level
-45.2M
20-day SMA
Buy
Level
$1.40
Relative Strength Index (RSI14)
Buy
Level
50.82
ADX Line
Sell
Level
28.94
Williams %R
Sell
Level
-8.5714
50-day SMA
Sell
Level
$1.58
MACD (12, 26)
Sell
Level
-0.05
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Neutral
Level
173.6M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.9503)
Buy
CA Score
(Annual)
Level (0.9445)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (2.7314)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
Stock Forecast FAQ
In the current month, MNOV has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MNOV average analyst price target in the past 3 months is $8.33.
-
Where Will MediciNova Stock Be In 1 Year?
According to analysts, the consensus estimate is that MediciNova share price will rise to $8.33 per share over the next 12 months.
-
What Do Analysts Say About MediciNova?
Analysts are divided on their view about MediciNova share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that MediciNova is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is MediciNova's Price Target?
The price target for MediciNova over the next 1-year time period is forecast to be $8.33 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MNOV A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for MediciNova is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MNOV?
You can purchase shares of MediciNova via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase MediciNova shares.
-
What Is The MediciNova Share Price Today?
MediciNova was last trading at $1.42 per share. This represents the most recent stock quote for MediciNova. Yesterday, MediciNova closed at $1.45 per share.
-
How To Buy MediciNova Stock Online?
In order to purchase MediciNova stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Baidu Stock a Sleeper AI Winner?
Although the recent policy decisions have gripped the market now,…
JPMorgan Is The Rally Over?
JPMorgan Chase (NYSE:JPM) share price is up 29% over the…
Stock Ideas
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 32x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 31x
Sell
46
Is NVDA Stock a Buy?
Market Cap: $2.5T
P/E Ratio: 35x
Alerts
Sell
23
UNH alert for Apr 19
UnitedHealth Group [UNH] is down 22.4% over the past day.
Sell
32
MAN alert for Apr 19
ManpowerGroup [MAN] is down 19.07% over the past day.
Sell
24
GPN alert for Apr 19
Global Payments [GPN] is down 17.44% over the past day.
